Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 209.09 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $36.250 million which missed the analyst consensus estimate of $43.300 million by 16.28 percent. This is a 58.19 percent decrease over sales of $86.700 million the same period last year.